Cargando…

A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients

Fludarabine, cyclophosphamide, and rituximab (FCR) is highly effective initial therapy for younger patients with chronic lymphocytic leukemia (CLL); however, most eventually relapse. Duvelisib is a delta/gamma PI3K inhibitor approved for relapsed/refractory CLL. We conducted an investigator-initiate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davids, Matthew S., Fisher, David C., Tyekucheva, Svitlana, McDonough, Mikaela, Hanna, John, Lee, Brandon, Francoeur, Karen, Montegaard, Josie, Odejide, Oreofe, Armand, Philippe, Arnason, Jon, Brown, Jennifer R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895867/ https://www.ncbi.nlm.nih.gov/pubmed/32820271 http://dx.doi.org/10.1038/s41375-020-01010-6

Ejemplares similares

A T Cell Inflammatory Phenotype is Associated with Autoimmune Toxicity of the PI3K Inhibitor Duvelisib in Chronic Lymphocytic Leukemia
por: Gadi, Deepti, et al.
Publicado: (2022)

Telomere length predicts for outcome to FCR chemotherapy in CLL
por: Norris, Kevin, et al.
Publicado: (2019)

Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)
por: Kutsch, Nadine, et al.
Publicado: (2020)

Therapy-related Myeloid Neoplasms in Patients With Chronic Lymphocytic Leukemia Who Received FCR/FC as Frontline Therapy
por: Laribi, Kamel, et al.
Publicado: (2022)

Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma
por: Merryman, Reid W., et al.
Publicado: (2023)

Unidimensional scales for fears of cancer recurrence and their psychometric properties: the FCR4 and FCR7
por: Humphris, G. M., et al.
Publicado: (2018)

Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies
por: Thompson, Philip A., et al.
Publicado: (2018)

Frontline Treatment of the Young, Fit Patient with CLL: A Canadian Perspective
por: Costello, Jacqueline, et al.
Publicado: (2021)

PB1875: TREATMENT OF YOUNGER PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN TUNISIA: FCR STILL STANDARD FOR FIRST-LINE THERAPY
por: Miled, W., et al.
Publicado: (2022)

Antitumor effects of duvelisib on Epstein–Barr virus‐associated lymphoma cells
por: Kawada, Jun‐ichi, et al.
Publicado: (2018)

A Double-Blind, Randomized Comparison Study between Zytux™ vs MabThera® in Treatment of CLL with FCR Regimen: Non-Inferiority Clinical Trial
por: Toogeh, Gholamreza, et al.
Publicado: (2018)

Human FcR Polymorphism and Disease
por: Li, Xinrui, et al.
Publicado: (2014)

Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5′-deoxy-5-fluorocytidine (5′-DFCR)
por: Gao, Yanyun, et al.
Publicado: (2021)

Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial
por: Herling, Carmen D., et al.
Publicado: (2020)

Prognostic Significance of PET/CT in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Chemoimmunotherapy
por: Porrazzo, Marika, et al.
Publicado: (2020)

Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases
por: Rodrigues, Daniel A., et al.
Publicado: (2019)

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

Interpretation of normal anatomic structures on chest radiography: Comparison of Fuji Computed Radiography (FCR) 5501D with FCR 5000 and screen‐film system
por: Nakashima, Kazuaki, et al.
Publicado: (2003)

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
por: Siddiqi, Tanya, et al.
Publicado: (2022)

Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies
por: Pepper, Andrea G. S., et al.
Publicado: (2021)

Blocking of FcR Suppresses the Intestinal Invasion of Scrapie Agents
por: Uraki, Ryuta, et al.
Publicado: (2011)

Development and validation of an UPLC-ESI-MS/MS method for quantification of duvelisib in plasma: application to pharmacokinetic study in rats
por: Darwish, Ibrahim A., et al.
Publicado: (2023)

Precancer and cancer-associated depression and anxiety among older adults with blood cancers in the United States
por: Kuczmarski, Thomas M., et al.
Publicado: (2022)

Effect of Duvelisib, a Selective PI3K Inhibitor on Seizure Activity in Pentylenetetrazole-Induced Convulsions Animal Model
por: Abdolrahmani, Mahnaz, et al.
Publicado: (2023)

Meaningful changes in end-of-life care among patients with myeloma
por: Odejide, Oreofe O., et al.
Publicado: (2018)

Duvelisib attenuates bleomycin‐induced pulmonary fibrosis via inhibiting the PI3K/Akt/mTOR signalling pathway
por: Li, Xiaohe, et al.
Publicado: (2023)

Duvelisib for Critically Ill Patients With Coronavirus Disease 2019: An Investigator-Initiated, Randomized, Placebo-Controlled, Double-Blind Pilot Trial
por: Goldsmith, Scott R, et al.
Publicado: (2023)

T cell receptor-independent CD2 signal transduction in FcR+ cells
Publicado: (1991)

Phospholipid Scramblase 1 Modulates FcR-Mediated Phagocytosis in Differentiated Macrophages
por: Herate, Cecile, et al.
Publicado: (2016)

Insulin-regulated aminopeptidase contributes to setting the intensity of FcR-mediated inflammation
por: Bratti, Manuela, et al.
Publicado: (2022)

CD160 receptor in CLL: Current state and future avenues
por: Oumeslakht, Loubna, et al.
Publicado: (2022)

Integrating diverse genomic data using gene sets
por: Tyekucheva, Svitlana, et al.
Publicado: (2011)

Extra-Neutralizing FcR-Mediated Antibody Functions for a Universal Influenza Vaccine
por: Boudreau, Carolyn M., et al.
Publicado: (2019)

Secondary malignancies and survival of FCR‐treated patients with chronic lymphocytic leukemia in Central Europe
por: Kósa, Fruzsina, et al.
Publicado: (2022)

Proximal humerus fracture management and outcomes are distinctly different for individuals 60 years of age or younger: a systematic review
por: Cognetti, Daniel J., et al.
Publicado: (2023)

The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies
por: Faia, Kerrie, et al.
Publicado: (2018)

A Highly Sensitive Nonextraction-Assisted HPLC Method with Fluorescence Detection for Quantification of Duvelisib in Plasma Samples and its Application to Pharmacokinetic Study in Rats
por: Sayed, Ahmed Y, et al.
Publicado: (2021)

P1172: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL: UPDATED EXPANSION PHASE ANALYSIS
por: Zinzani, P. L., et al.
Publicado: (2022)

CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)

The Xenopus FcR family demonstrates continually high diversification of paired receptors in vertebrate evolution
por: Guselnikov, Sergey V, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_0grj573lrdtum7bo82lfeo16av